Print Friendly, PDF & Email

NCT/Study#

NA /

LAVA-051

A Phase 1 And 2a Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity And Antitumor Activity Of LAVA-051 In Patients With Relapsed Or Refractory CD1d-Positive Chronic Lymphocytic Leukemia, Multiple Myeloma Or Acute Myeloid Leukemia

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I/II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: